Cargando…

Hypertension and overall survival in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy

BACKGROUND: Hypertension (HTN) is a common toxicity of anti-VEGF (vascular endothelial growth factor) antibody treatment. It may be a marker of VEGF signalling pathway inhibition and therefore represent a cancer biomarker in metastatic colorectal cancer (mCRC) patients treated with chemotherapy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Österlund, P, Soveri, L-M, Isoniemi, H, Poussa, T, Alanko, T, Bono, P
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2011
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049598/ https://www.ncbi.nlm.nih.gov/pubmed/21304526 http://dx.doi.org/10.1038/bjc.2011.2

Ejemplares similares

A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection
por: Osterlund, Pia, et al.
Publicado: (2014)

Helicobacter pylori and gastrointestinal symptoms in diagnostics and adjuvant chemotherapy of colorectal cancer
por: SOVERI, LEENA-MAIJA, et al.
Publicado: (2014)

Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival
por: Paiva, Tadeu Ferreira, et al.
Publicado: (2015)

Resectability, Resections, Survival Outcomes, and Quality of Life in Older Adult Patients with Metastatic Colorectal Cancer (the RAXO-Study)
por: Lehtomäki, Kaisa, et al.
Publicado: (2023)

Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer
por: Wu, Qian, et al.
Publicado: (2013)

Tumor Size and Overall Survival in Patients With Platinum-Resistant Ovarian Cancer Treated With Chemotherapy and Bevacizumab
por: Sostelly, Alexandre, et al.
Publicado: (2019)

Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer
por: LIM, SUNG HEE, et al.
Publicado: (2023)

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer
por: Loupakis, Fotios, et al.
Publicado: (2015)

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer
por: Feliu, Jaime, et al.
Publicado: (2015)

Lung metastasectomy for colorectal cancer in the PulMiCC randomised controlled trial – Authors’ reply
por: Osterlund, Pia, et al.
Publicado: (2021)

Health-Related Quality of Life in Metastatic Colorectal Cancer Patients Treated with Curative Resection and/or Local Ablative Therapy or Systemic Therapy in the Finnish RAXO-Study
por: Lehtomäki, Kaisa, et al.
Publicado: (2022)

Efficacy of bevacizumab-containing chemotherapy in metastatic colorectal cancer and CXCL5 expression: Six case reports
por: Novillo, Apolonia, et al.
Publicado: (2020)

Repeated centralized multidisciplinary team assessment of resectability, clinical behavior, and outcomes in 1086 Finnish metastatic colorectal cancer patients (RAXO): A nationwide prospective intervention study
por: Osterlund, Pia, et al.
Publicado: (2021)

Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
por: Cai, Jun, et al.
Publicado: (2013)

Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study
por: Lu, Linbin, et al.
Publicado: (2019)

Consumption of Lactose, Other FODMAPs and Diarrhoea during Adjuvant 5-Fluorouracil Chemotherapy for Colorectal Cancer
por: Holma, Reetta, et al.
Publicado: (2020)

Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis
por: Ilic, Irena, et al.
Publicado: (2016)

Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer
por: Yang, Qiong, et al.
Publicado: (2015)

Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy
por: Cybulska-Stopa, Bożena, et al.
Publicado: (2020)

Portal Vein Thrombosis in Metastatic Colorectal Cancer During FOLFIRI-bevacizumab Chemotherapy Successfully Treated with Apixaban
por: Fujiwara, Yu, et al.
Publicado: (2020)

Second-line chemotherapy after early disease progression during first-line chemotherapy containing bevacizumab for patients with metastatic colorectal cancer
por: Yamamoto, Shun, et al.
Publicado: (2021)

The Impact of Bevacizumab and Chemotherapy on Quality of Life in Metastatic Colorectal Cancer Patients
por: Moisuc, Diana Cornelia, et al.
Publicado: (2023)

The impact of microsatellite instability status and sidedness of the primary tumor on the effect of bevacizumab-containing chemotherapy in patients with metastatic colorectal cancer
por: Kim, Seung Tae, et al.
Publicado: (2018)

Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients
por: Abajo, A, et al.
Publicado: (2012)

Bevacizumab plus chemotherapy as salvage treatment in chemorefractory patients with metastatic colorectal cancer
por: Geva, Ravit, et al.
Publicado: (2013)

The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer
por: Yin, Chenxi, et al.
Publicado: (2016)

In Reply: Overall Survival of Resectable Metastatic Colon Cancer Treated With Neoadjuvant Chemotherapy or Adjuvant Chemotherapy in Non-academic Program
por: Hao, Zhonglin, et al.
Publicado: (2023)

The Prognostic and Predictive Value of Carbohydrate Antigen 19-9 in Metastatic Colorectal Cancer Patients with First Line Bevacizumab Containing Chemotherapy
por: Jiang, Chang, et al.
Publicado: (2017)

Occurence of RAS reversion in metastatic colorectal cancer patients treated with bevacizumab
por: Epistolio, Samantha, et al.
Publicado: (2021)

Metastatic colorectal cancer-prolonging overall survival with targeted therapies
por: Dattatreya, Satya
Publicado: (2013)

Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer
por: Garattini, Silvio Ken, et al.
Publicado: (2021)

Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases
por: Liu, Jin-Hwang, et al.
Publicado: (2010)

A Genetic Variant in CD274 Is Associated With Prognosis in Metastatic Colorectal Cancer Patients Treated With Bevacizumab-Based Chemotherapy
por: Qin, Wan, et al.
Publicado: (2022)

KRAS-G12C Mutation in One Real-Life and Three Population-Based Nordic Cohorts of Metastatic Colorectal Cancer
por: Osterlund, Emerik, et al.
Publicado: (2022)

Chemotherapy plus Panitumumab Versus Chemotherapy plus Bevacizumab in Metastatic Colorectal Cancer: A Meta-analysis
por: Li, Zhigui, et al.
Publicado: (2018)

Association of Neoadjuvant Chemotherapy With Overall Survival in Women With Metastatic Endometrial Cancer
por: Tobias, Claire J., et al.
Publicado: (2020)

Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients
por: Hoeh, Benedikt, et al.
Publicado: (2021)

Efficacy of chemotherapy on overall survival in metastatic sarcomatoid bladder cancer patients
por: Tappero, Stefano, et al.
Publicado: (2022)

Resectability, conversion, metastasectomy and outcome according to RAS and BRAF status for metastatic colorectal cancer in the prospective RAXO study
por: Uutela, Aki, et al.
Publicado: (2022)

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3jn5urfhg0ccfeqj849ubqrul6